[Dopamine agonists in the therapy of parkinson syndrome].
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001667:Binding, Competitive; D001971:Bromocriptine / Q000627:therapeutic use; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008090:Lisuride / Q000627:therapeutic use; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010891:Piribedil / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism
D000978:Antiparkinson Agents; D011954:Receptors, Dopamine; D001971:Bromocriptine; D007980:Levodopa; D010891:Piribedil; D008090:Lisuride; D004298:Dopamine
Dopaminagonisten in der Therapie des Parkinsonsyndroms.